IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit August 19, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
FAILED TRIAL: Clinical but not significant PFS Improvement seen in Ph 3 Trial of Cylembio® plus KEYTRUDA® in 1L Advanced Melanoma August 12, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
Mid-year report of Ampligen® (rintatolimod) & Imfinzi® combo in pancreatic cancer demonstrates no significant toxicity and superior PFS and OS August 12, 2025
24-Month DOR of 72.2% Announced from Ph 3 ENVISION Trial of ZUSDURI in Recurrent Low-Grade Intermediate-Risk NMIBC August 12, 2025
Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43% August 11, 2025
Positive Data Announced from Ph 2 CRDF-004 trial of onvansertib in 1L RAS-mutated mCRC August 5, 2025
Final Clinical Data Update from the NXP800 Ph 1b Study in Ovarian Cancer Provided and Completion of the NXP900 Ph 1a Dose Escalation Study Reported August 5, 2025
Jaypirca (pirtobrutinib) met primary endpoint in a head-to-head Ph 3 trial versus Imbruvica (ibrutinib) in CLL/SLL August 5, 2025
Preliminary Safety & Efficacy Data Announced from Trial of IMM2510/AXN-2510 in Combination with Chemo in 1L NSCLC in China August 5, 2025
Clinically Meaningful Improvement in Both PFS Primary Endpoints from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Trial Announced July 29, 2025
Positive Data from Long-Term Follow-Up Analysis of the Ph 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated AML Announced July 29, 2025
Complete Response Reported in Heavily Pre-Treated Lymphoma Patient with LP-284 in Ph 1 Trial July 29, 2025
Positive Mid-year Safety and Efficacy Data from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi Combo for the Treatment of Pancreatic Cancer Reported July 29, 2025
Ph 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent LGIR-NMIBC published in Reviews in Urology July 29, 2025
Preliminary topline efficacy results from Ph 2 TRIFOUR trial of nadunolimab in advanced TNBC announced July 23, 2025
Tagrisso + chemo demonstrated statistically significant and clinically meaningful improvement in OS in EGFR-mutated advanced lung cancer July 23, 2025
All Primary Endpoints Met in Ph 2 Trial of SLS009 in R/R AML; FDA Guidance Received to Advance into 1L Therapy Study July 23, 2025
Positive Safety Results from Ph 2 Trial of ENV-105 in Advanced Prostate Cancer Announced July 23, 2025
Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with LGIR NMIBC Announced July 23, 2025
XTANDI + Leuprolide combo Significantly Improves Survival Outcomes in Men with Non-Metastatic HSPC with High-Risk Biochemical Recurrence July 15, 2025
Encouraging Response Rates Announced from Ph 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL July 15, 2025
